Immuron Limited (ASX:IMC) Reports Strong Travelan® Sales Growth
Sales Growth Overview
Immuron Limited (ASX: IMC) reported significant growth in sales of its immune supplement, Travelan®. The company achieved global sales of AUD $2.5 million in the December 2024 quarter, marking a remarkable 70% increase compared to the previous quarter and a substantial 249% rise over the prior corresponding period (pcp). For the half year ending December 2024, sales reached AUD $4.0 million, representing a 70% increase year-on-year.
Regional Performance
In Australia, Travelan® sales surged to AUD $1.9 million in the December 2024 quarter, an 83% increase from the prior quarter and a 314% increase from December 2023. For the December 2024 half year, sales totalled AUD $2.9 million, a 54% rise compared to the same period last year.
In North America, sales also climbed, with the December 2024 quarter generating AUD $0.7 million, a 43% increase sequentially and 141% on pcp. The total for the half year stood at AUD $1.1 million, a dramatic 130% increase over the prior year. The sales in the U.S. and Canada were AUD $0.731 million and AUD $0.376 million, respectively.
Executive Comments
Flavio Palumbo, Chief Commercial Officer, stated, “We are achieving strong growth in both Australia and North America, reflecting the core ranging we secured in another nine pharmacy banner groups in Australia, distribution in ten pharmacy/grocery retailers in Canada, and sales growth on Amazon in the U.S.”
About Travelan®
Travelan® is an over-the-counter oral immunotherapy designed to mitigate the risk of travelers’ diarrhea caused by pathogenic bacteria. The product is available as a listed medicine in Australia and as a dietary supplement in the U.S., targeting digestive tract protection.
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.